Cyclerion Therapeutics,Inc. (CYCN)
NASDAQ:CYCN
CYCN Stock Chart & Stats
$6.15
$0.00(0.00%)
At close: 4:00 PM EST
$6.15
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.03 - $8.48
Previous CloseN/A
Volume28.13K
Average Volume (3M)162.78K
Market Cap
$26.63M
Enterprise Value$18.84M
Total Cash (Recent Filing)$4.57M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.33
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,330,314
10 Day Avg. Volume35,401
30 Day Avg. Volume162,776
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.92
Price to Sales (P/S)4.05
P/FCF Ratio-1.87
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue6.60
Enterprise Value/Gross Profit6.60
Enterprise Value/Ebitda-5.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Equity PositionA strong equity position with no debt provides financial stability and flexibility, allowing Cyclerion to focus on R&D without the pressure of debt repayments.
High Gross Profit MarginMaintaining a high gross profit margin indicates efficient cost management in revenue-generating years, which is crucial for future profitability as the company scales.
Focus On CNS DisordersTargeting CNS disorders with high unmet needs positions Cyclerion to potentially capture significant market share if their therapies succeed, driving long-term growth.
Bears Say
Persistent Net LossesOngoing net losses highlight operational inefficiencies and the challenge of achieving profitability, which can hinder long-term financial health and investment capacity.
Negative Cash FlowNegative cash flow restricts Cyclerion's ability to invest in R&D and scale operations, potentially limiting future growth and sustainability.
Inconsistent Revenue GrowthInconsistent revenue growth reflects challenges in product development and market penetration, which could affect long-term viability and investor confidence.
Cyclerion Therapeutics News
CYCN FAQ
What was Cyclerion Therapeutics,Inc.’s price range in the past 12 months?
Cyclerion Therapeutics,Inc. lowest stock price was $1.03 and its highest was $8.48 in the past 12 months.
What is Cyclerion Therapeutics,Inc.’s market cap?
Cyclerion Therapeutics,Inc.’s market cap is $26.63M.
When is Cyclerion Therapeutics,Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cyclerion Therapeutics,Inc.’s earnings last quarter?
Currently, no data Available
Is Cyclerion Therapeutics,Inc. overvalued?
According to Wall Street analysts Cyclerion Therapeutics,Inc.’s price is currently Overvalued.
Does Cyclerion Therapeutics,Inc. pay dividends?
Cyclerion Therapeutics,Inc. does not currently pay dividends.
What is Cyclerion Therapeutics,Inc.’s EPS estimate?
Cyclerion Therapeutics,Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyclerion Therapeutics,Inc. have?
Cyclerion Therapeutics,Inc. has 4,330,314 shares outstanding.
What happened to Cyclerion Therapeutics,Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cyclerion Therapeutics,Inc.?
Currently, no hedge funds are holding shares in CYCN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cyclerion Therapeutics,Inc.
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Technical Analysis
Ownership Overview
15.03%
Insiders
0.87% Mutual Funds
2.95% Other Institutional Investors
80.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---